Teladoc (TDOC) director granted 53,648 restricted stock units in equity award

Rhea-AI Filing Summary

Smith Michael S reported acquisition or exercise transactions in this Form 4 filing.

Teladoc Health, Inc. director Michael S. Smith received a grant of 53,648 restricted stock units, each representing the right to receive one share of TDOC common stock. One-third of these units vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Michael S

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/18/2026		A		53,648		(2)	(2)	Common Stock	53,648	$0	53,648	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.

2. One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teladoc Health (TDOC) report for Michael S. Smith?

Teladoc Health reported that director Michael S. Smith received a grant of 53,648 restricted stock units. These units are a form of equity compensation that may convert into Teladoc common shares if the vesting conditions and schedule are satisfied over time.

How many restricted stock units did the Teladoc (TDOC) director receive?

Michael S. Smith received 53,648 restricted stock units. Each unit represents a contingent right to receive one share of Teladoc Health common stock, providing potential future ownership if the units fully vest according to the specified multi-year vesting schedule.

What does each restricted stock unit represent for Teladoc (TDOC) equity awards?

Each restricted stock unit granted to Michael S. Smith represents a contingent right to receive one share of TDOC common stock. Actual share delivery depends on satisfying the vesting schedule and any applicable conditions tied to continued service with Teladoc Health.

What is the vesting schedule for Michael S. Smith’s Teladoc (TDOC) RSU grant?

One-third of Michael S. Smith’s restricted stock units vest on the first anniversary of the grant date. The remaining units vest in eight substantially equal quarterly installments, spreading the vesting over several years and aligning long-term incentives with Teladoc Health’s performance.

Did Michael S. Smith pay a price per share for the Teladoc (TDOC) RSU grant?

The reported transaction price per share for Michael S. Smith’s restricted stock units is 0.0000. This reflects that RSU grants are typically awarded as compensation and do not require the director to pay cash to acquire the underlying Teladoc common shares.

How many Teladoc (TDOC) restricted stock units does Michael S. Smith hold after this grant?

Following the reported transaction, Michael S. Smith beneficially owns 53,648 restricted stock units directly. These units may settle into an equivalent number of Teladoc Health common shares over time, subject to the described vesting schedule and any ongoing service requirements.